134 related articles for article (PubMed ID: 37011376)
1. Chemoimmunological Cascade Cancer Therapy Using Fluorine Assembly Nanomedicine.
Zhang Q; Wu P; Wu J; Shou H; Ming X; Wang S; Wang B
ACS Nano; 2023 Apr; 17(8):7498-7510. PubMed ID: 37011376
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapeutic drug-induced immunogenic cell death for nanomedicine-based cancer chemo-immunotherapy.
Jiang M; Zeng J; Zhao L; Zhang M; Ma J; Guan X; Zhang W
Nanoscale; 2021 Oct; 13(41):17218-17235. PubMed ID: 34643196
[TBL] [Abstract][Full Text] [Related]
3. Breast Cancer Chemo-immunotherapy through Liposomal Delivery of an Immunogenic Cell Death Stimulus Plus Interference in the IDO-1 Pathway.
Lu J; Liu X; Liao YP; Wang X; Ahmed A; Jiang W; Ji Y; Meng H; Nel AE
ACS Nano; 2018 Nov; 12(11):11041-11061. PubMed ID: 30481959
[TBL] [Abstract][Full Text] [Related]
4. Plasmon-Driven Catalytic Chemotherapy Augments Cancer Immunotherapy through Induction of Immunogenic Cell Death and Blockage of IDO Pathway.
Ding Y; Sun Z; Gao Y; Zhang S; Yang C; Qian Z; Jin L; Zhang J; Zeng C; Mao Z; Wang W
Adv Mater; 2021 Aug; 33(34):e2102188. PubMed ID: 34278622
[TBL] [Abstract][Full Text] [Related]
5. Polymer-lipid hybrid nanovesicle-enabled combination of immunogenic chemotherapy and RNAi-mediated PD-L1 knockdown elicits antitumor immunity against melanoma.
Wang C; Shi X; Song H; Zhang C; Wang X; Huang P; Dong A; Zhang Y; Kong D; Wang W
Biomaterials; 2021 Jan; 268():120579. PubMed ID: 33278683
[TBL] [Abstract][Full Text] [Related]
6. Phosphorous Dendron Micelles as a Nanomedicine Platform for Cooperative Tumor Chemoimmunotherapy via Synergistic Modulation of Immune Cells.
Zhan M; Qiu J; Fan Y; Chen L; Guo Y; Wang Z; Li J; Majoral JP; Shi X
Adv Mater; 2023 Jan; 35(3):e2208277. PubMed ID: 36300810
[TBL] [Abstract][Full Text] [Related]
7. Combining Nanomedicine and Immunotherapy.
Shi Y; Lammers T
Acc Chem Res; 2019 Jun; 52(6):1543-1554. PubMed ID: 31120725
[TBL] [Abstract][Full Text] [Related]
8. Co-localized delivery of nanomedicine and nanovaccine augments the postoperative cancer immunotherapy by amplifying T-cell responses.
Liu X; Feng Z; Wang C; Su Q; Song H; Zhang C; Huang P; Liang XJ; Dong A; Kong D; Wang W
Biomaterials; 2020 Feb; 230():119649. PubMed ID: 31791843
[TBL] [Abstract][Full Text] [Related]
9. Multi-functional nanomedicines for combinational cancer immunotherapy that transform cold tumors to hot tumors.
Cho H; Kim K
Expert Opin Drug Deliv; 2024 Apr; 21(4):627-638. PubMed ID: 38682272
[TBL] [Abstract][Full Text] [Related]
10. Nanomicelle protects the immune activation effects of Paclitaxel and sensitizes tumors to anti-PD-1 Immunotherapy.
Yang Q; Shi G; Chen X; Lin Y; Cheng L; Jiang Q; Yan X; Jiang M; Li Y; Zhang H; Wang H; Wang Y; Wang Q; Zhang Y; Liu Y; Su X; Dai L; Tang M; Li J; Zhang L; Qian Z; Yu D; Deng H
Theranostics; 2020; 10(18):8382-8399. PubMed ID: 32724476
[TBL] [Abstract][Full Text] [Related]
11. CD4
Xiao M; Xie L; Cao G; Lei S; Wang P; Wei Z; Luo Y; Fang J; Yang X; Huang Q; Xu L; Guo J; Wen S; Wang Z; Wu Q; Tang J; Wang L; Chen X; Chen C; Zhang Y; Yao W; Ye J; He R; Huang J; Ye L
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35580929
[TBL] [Abstract][Full Text] [Related]
12. TRAIL-modified, doxorubicin-embedded periodic mesoporous organosilica nanoparticles for targeted drug delivery and efficient antitumor immunotherapy.
Feng X; Li F; Zhang L; Liu W; Wang X; Zhu R; Qiao ZA; Yu B; Yu X
Acta Biomater; 2022 Apr; 143():392-405. PubMed ID: 35259519
[TBL] [Abstract][Full Text] [Related]
13. Immunogenic radiation therapy for enhanced anti-tumor immunity
Huang N; Qian A; Zou Y; Lin M; Pan W; Chen M; Meng W; Zhang W; Chen J
Theranostics; 2023; 13(12):4121-4137. PubMed ID: 37554266
[No Abstract] [Full Text] [Related]
14. Doxorubicin-Near infrared dye conjugate induces immunogenic cell death to enhance cancer immunotherapy.
Jin C; Wang Y; Li Y; Li J; Zhou S; Yu J; Wang Z; Yu Y; Zhang H; Wang D; He Z; Wang Y
Int J Pharm; 2021 Sep; 607():121027. PubMed ID: 34418473
[TBL] [Abstract][Full Text] [Related]
15. Dendritic Nanomedicine with Boronate Bonds for Augmented Chemo-Immunotherapy via Synergistic Modulation of Tumor Immune Microenvironment.
Li Y; Wu Y; Fang Z; Zhang Y; Ding H; Ren L; Zhang L; Gong Q; Gu Z; Luo K
Adv Mater; 2024 Jan; 36(2):e2307263. PubMed ID: 37743633
[TBL] [Abstract][Full Text] [Related]
16. Utilizing chemotherapy-induced tumor RNA nanoparticles to improve cancer chemoimmunotherapy.
Su L; Pan W; Li X; Zhou X; Ma X; Min Y
Acta Biomater; 2023 Mar; 158():698-707. PubMed ID: 36563773
[TBL] [Abstract][Full Text] [Related]
17. The potentiated checkpoint blockade immunotherapy by ROS-responsive nanocarrier-mediated cascade chemo-photodynamic therapy.
Hu L; Cao Z; Ma L; Liu Z; Liao G; Wang J; Shen S; Li D; Yang X
Biomaterials; 2019 Dec; 223():119469. PubMed ID: 31520886
[TBL] [Abstract][Full Text] [Related]
18. Crizotinib prodrug micelles co-delivered doxorubicin for synergistic immunogenic cell death induction on breast cancer chemo-immunotherapy.
Liang Q; Lan Y; Li Y; Cao Y; Li J; Liu Y
Eur J Pharm Biopharm; 2022 Aug; 177():260-272. PubMed ID: 35863668
[TBL] [Abstract][Full Text] [Related]
19. Prodrug-Based Versatile Nanomedicine for Enhancing Cancer Immunotherapy by Increasing Immunogenic Cell Death.
Bai S; Yang LL; Wang Y; Zhang T; Fu L; Yang S; Wan S; Wang S; Jia D; Li B; Xue P; Kang Y; Sun ZJ; Xu Z
Small; 2020 May; 16(19):e2000214. PubMed ID: 32309900
[TBL] [Abstract][Full Text] [Related]
20. Activation of NKT Cells in an Anti-PD-1-Resistant Tumor Model Enhances Antitumor Immunity by Reinvigorating Exhausted CD8 T Cells.
Bae EA; Seo H; Kim BS; Choi J; Jeon I; Shin KS; Koh CH; Song B; Kim IK; Min BS; Han YD; Shin SJ; Kang CY
Cancer Res; 2018 Sep; 78(18):5315-5326. PubMed ID: 30012672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
